Harborside advises a Philadelphia based manufacturer in a pharmaceutical acquisition

Harborside advises a Philadelphia based manufacturing company on a completed acquisition of a Princeton New Jersey pharmaceutical company. The transaction positions the company as a “major player” in the consolidating generic drug industry. The target was a specialty generic pharmaceuticals subsidiary of global company and a highly profitable business. The acquisition that extends the size, scale and reach of the strategically diversified product portfolio and pipeline. Additionally, the target company added complementary research and development expertise. The deal moved forward despite being informed earlier this month and the combined company generated revenues in excess of $750 million in 2015. The combination of proceeds of a recently completed financing leaves the company with a strong balance sheet.

Leave a Reply